Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) EPS (Basic) (2021 - 2025)

Kiniksa Pharmaceuticals International's EPS (Basic) history spans 5 years, with the latest figure at $0.19 for Q4 2025.

  • For Q4 2025, EPS (Basic) rose 258.33% year-over-year to $0.19; the TTM value through Dec 2025 reached $0.8, up 231.15%, while the annual FY2025 figure was $0.8, 233.33% up from the prior year.
  • EPS (Basic) reached $0.19 in Q4 2025 per KNSA's latest filing, down from $0.25 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $3.23 in Q3 2022 to a low of -$0.72 in Q1 2021.
  • Average EPS (Basic) over 5 years is $0.04, with a median of -$0.15 recorded in 2023.
  • Peak YoY movement for EPS (Basic): skyrocketed 834.09% in 2022, then crashed 133.33% in 2024.
  • A 5-year view of EPS (Basic) shows it stood at -$0.52 in 2021, then soared by 111.54% to $0.06 in 2022, then soared by 500.0% to $0.36 in 2023, then crashed by 133.33% to -$0.12 in 2024, then soared by 258.33% to $0.19 in 2025.
  • Per Business Quant, the three most recent readings for KNSA's EPS (Basic) are $0.19 (Q4 2025), $0.25 (Q3 2025), and $0.24 (Q2 2025).